| Literature DB >> 29115971 |
L M Rubio-Martínez1, E Rioja2, M Castro Martins2, S Wipawee3, P Clegg4, M J Peffers4.
Abstract
BACKGROUND: Chondrotoxic effects of local anaesthetics are well reported in humans and some animal species but knowledge on their toxic effects on synoviocytes or equine chondrocytes or the effects on cellular production of inflammatory cytokines is limited. The purpose of this study was to evaluate the in vitro effects of local anaesthetics, morphine, magnesium sulphate (MgSO4) or their combinations on cell viability and pro-inflammatory cytokine gene expression of equine synoviocytes and chondrocytes. Equine synoviocytes and cartilage explants harvested from normal joints in a co-culture system were exposed to mepivacaine (4.4 mg/ml), bupivacaine (2.2 mg/ml), morphine (2.85 mg/ml) and MgSO4 (37 mg/ml) alone or each local anaesthetic plus morphine or MgSO4 or both together. Chondrocyte and synoviocyte cell viability was assessed by CellTiter-Glo Luminescent Cell Viability Assay. Synoviocyte gene expression of IL-1β, IL-6 or TNF-α was measured and compared using the ∆∆CT method.Entities:
Keywords: Chondrocyte; Equine; Local anaesthetic; Magnesium sulphate; Morphine; Synoviocyte
Mesh:
Substances:
Year: 2017 PMID: 29115971 PMCID: PMC5678813 DOI: 10.1186/s12917-017-1244-8
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Treatment groups
| Group | Treatment |
|---|---|
| 1 | Control |
| 2 | Mepivacaine only |
| 3 | Mepivacaine + morphine |
| 4 | Mepivacaine + MgSO4 |
| 5 | Mepivacaine + morphine + MgSO4 |
| 6 | Morphine only |
| 7 | MgSO4 only |
| 8 | Morphine + MgSO4 |
| 9 | Bupivacaine only |
| 10 | Bupivacaine + morphine |
| 11 | Bupivacaine + MgSO4 |
| 12 | Bupivacaine + morphine + MgSO4 |
Treatment groups to which synoviocyte-articular cartilage explant co-cultures were exposed. Concentrations used were mepivacaine 4.4 mg/ml, bupivacaine 2.2 mg/ml, morphine 2.85 mg/ml and magnesium sulphate 37 mg/ml diluted in DMEM complete to a total volume of 2 ml per well
Primer sequences of the reference gene (GAPDH) and pro-inflammatory cytokines IL1β, IL6 and TNFα used in the study
| Gene | GeneBank Accession | Direction | Primer Sequence (5′-3′) |
|---|---|---|---|
| GAPDH | NM_001163856 | Forward | GCATCGTGGAGGGACTCA |
| Reverse | GCCACATCTTCCCAGAGG | ||
| IL-1β | NM_001317261 | Forward | GCCTAAGAATACTACATCCAGAGA |
| Reverse | GGCATTGATTAGACAACAGTGAA | ||
| IL-6 | NM_001082496 | Forward | CTGCTCCTCGTGATGGCTAC |
| Reverse | CCGAGGATGTACTTAATGTGCTG | ||
| TNF-α | NM_001081819 | Forward | CCTTCCACTCAATCAACCCTCT |
| Reverse | CACGCCCACTCAGCCACT |
Primer sequences of the reference gene (GAPDH) and proinflammatory cytokines IL1β, IL6 and TNFα used in the study
Fig. 1Synoviocyte viability Cell viability measured as luminescence signal (shown as log10 transformed Relative Light Units [RLU]) for synoviocytes exposed to different treatments (for further information on treatment groups refer to Table 1). Error bars indicate 95% confidence interval. Asterisk (*) indicates significant difference (p < 0.05) with group 1 (control). Groups included are: control (group 1); mepivacaine (group 2); mepivacaine + morphine (group 3); mepivacaine + MgSO4 (group 4); mepivacaine + morphine + MgSO4 (group 5); morphine (group 6); MgSO4 (group 7); morphine + MgSO4 (group 8); bupivacaine (group 9); bupivacaine + morphine (group 10); bupivacaine + MgSO4 (group 11); and bupivacaine + morphine + MgSO4 (group 12)
Fig. 2Chondrocyte viability Cell viability measured as luminescence signal (mean values of Relative Light Units [RLU]) for chondrocytes exposed to different treatment groups (for further information on treatment groups refer to Table 1). Error bars indicate 95% confidence interval. Asterisk (*) indicates significant difference (p < 0.05) with group 1 (control). Groups included are: control (group 1); mepivacaine (group 2); mepivacaine + morphine (group 3); mepivacaine + MgSO4 (group 4); mepivacaine + morphine + MgSO4 (group 5); morphine (group 6); MgSO4 (group 7); morphine + MgSO4 (group 8); bupivacaine (group 9); bupivacaine + morphine (group 10); bupivacaine + MgSO4 (group 11); and bupivacaine + morphine + MgSO4 (group 12)
Fig. 3Synoviocyte IL1β gene expression IL1β gene expression (mean log102^-ΔCT) for synoviocytes exposed to different treatment groups (for further information on treatment groups refer to Table 1). Error bars indicate 95% confidence interval. Asterisk (*) indicates significant difference (p < 0.05) with group 1 (control). Groups included are: control (group 1); mepivacaine (group 2); mepivacaine + morphine (group 3); mepivacaine + MgSO4 (group 4); mepivacaine + morphine + MgSO4 (group 5); morphine (group 6); MgSO4 (group 7); morphine + MgSO4 (group 8); bupivacaine (group 9); bupivacaine + morphine (group 10); bupivacaine + MgSO4 (group 11); and bupivacaine + morphine + MgSO4 (group 12).
Fig. 4Synoviocyte IL6 gene expression IL6 gene expression (mean log102^-ΔCT) for synoviocytes exposed to different treatment groups (for further information on treatment groups refer to Table 1). Error bars indicate 95% confidence interval. Asterisk (*) indicates significant difference (p < 0.05) with group 1 (control). Groups included are: control (group 1); mepivacaine (group 2); mepivacaine + morphine (group 3); mepivacaine + MgSO4 (group 4); mepivacaine + morphine + MgSO4 (group 5); morphine (group 6); MgSO4 (group 7); morphine + MgSO4 (group 8); bupivacaine (group 9); bupivacaine + morphine (group 10); bupivacaine + MgSO4 (group 11); and bupivacaine + morphine + MgSO4 (group 12).
Fig. 5Synoviocyte TNFα gene expression (mean log102^-ΔCT) for synoviocytes exposed to different treatment groups (for further information on treatment groups refer to Table 1). Error bars indicate 95% confidence interval. Asterisk (*) indicates significant difference (p < 0.05) with group 1 (control). Groups included are: control (group 1); mepivacaine (group 2); mepivacaine + morphine (group 3); mepivacaine + MgSO4 (group 4); mepivacaine + morphine + MgSO4 (group 5); morphine (group 6); MgSO4 (group 7); morphine + MgSO4 (group 8); bupivacaine (group 9); bupivacaine + morphine (group 10); bupivacaine + MgSO4 (group 11); and bupivacaine + morphine + MgSO4 (group 12)